Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study.
Arthralgia
Colorectal cancer
Lung cancer
Ovarian cancer
Targeted therapy
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
06
10
2020
accepted:
29
12
2020
pubmed:
14
1
2021
medline:
25
8
2021
entrez:
13
1
2021
Statut:
ppublish
Résumé
The occurrence of arthralgia and myalgia during treatment with bevacizumab (Bev) has been described but not spontaneously reported. We aimed to evaluate the frequency of arthralgia in patients treated with Bev and identify the risk factors. In this observational prospective study, a self-administered questionnaire was distributed to patients at the initiation of Bev and at 3 and 6 months of treatment. Bev (5-15 mg/kg) was administered every 2 or 3 weeks, with or without chemotherapy. A total of 71 patients (42 with colorectal cancer, 22 with ovarian cancer, and 7 with lung cancer) were enrolled from January to November 2018. All patients completed the questionnaire at initiation, while only 56 (78.9%) and 36 (50.7%) patients completed the questionnaire at 3 and 6 months, respectively. The frequency of joint pain was 29.6% before Bev treatment and increased to 41.8% and 50% at 3 and 6 months, respectively, without reaching significance. The evolution of pain was significant according to the Common Terminology Criteria for Adverse Events grades (P = 0.032). No significant increase in the impact of pain on instrumental or elementary activities was observed over time. The frequency of arthralgia significantly increased at 3 months in patients with ovarian cancer versus those with colorectal cancer (odds ratio: 19.50; 95% confidence interval 4.53-83.98; P < 0.001). Bev‑including regimens tend to be associated with a significant increase in the frequency of arthralgia in women treated for ovarian cancer. Physicians should be aware of this side effect. NCT03455907, date of registration: March 7, 2018.
Identifiants
pubmed: 33438069
doi: 10.1007/s00280-020-04226-6
pii: 10.1007/s00280-020-04226-6
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Banques de données
ClinicalTrials.gov
['NCT03455907']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-541Références
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307. https://doi.org/10.1038/nature10144
doi: 10.1038/nature10144
pubmed: 21593862
pmcid: 4049445
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. https://doi.org/10.1056/NEJMoa032691
doi: 10.1056/NEJMoa032691
pubmed: 15175435
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550. https://doi.org/10.1056/NEJMoa061884
doi: 10.1056/NEJMoa061884
pubmed: 17167137
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496. https://doi.org/10.1056/NEJMoa1103799
doi: 10.1056/NEJMoa1103799
pubmed: 22204725
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483. https://doi.org/10.1056/NEJMoa1104390
doi: 10.1056/NEJMoa1104390
pubmed: 22204724
Graceffa D, Maiani E, Pace A, Solivetti FM, Elia F, De Mutiis C et al (2012) Psoriatic arthritis during treatment with bevacizumab for anaplastic oligodendroglioma. Case Rep Rheumatol 2012:208606. https://doi.org/10.1155/2012/208606
doi: 10.1155/2012/208606
pubmed: 23243547
pmcid: 3517839
Jaishuen A, Berrios-Rivera JP, Sirisabya N, Zheng HG, Li Y, Kavanagh JJ (2008) Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary. Int J Gynecol Cancer 18:379–383. https://doi.org/10.1111/j.1525-1438.2007.01023.x
doi: 10.1111/j.1525-1438.2007.01023.x
pubmed: 17624988
Datta-Mitra A, Riar NK, Raychaudhuri SP (2014) Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. Indian J Dermatol 59:632. https://doi.org/10.4103/0019-5154.143574
doi: 10.4103/0019-5154.143574
pubmed: 25484418
pmcid: 4248526
Nagai T, Sato M, Kobayashi M, Yokoyama M, Tani Y, Mochida J (2014) Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis. Arthritis Res Ther 16:427. https://doi.org/10.1186/s13075-014-0427-y
doi: 10.1186/s13075-014-0427-y
pubmed: 25230745
pmcid: 4189677
Thairu N, Kiriakidis S, Dawson P, Paleolog E (2011) Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis 14:223–234. https://doi.org/10.1007/s10456-011-9208-2
doi: 10.1007/s10456-011-9208-2
pubmed: 21431303
Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623–628. https://doi.org/10.1038/9467
doi: 10.1038/9467
pubmed: 10371499
Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL et al (1999) Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27:78–86. https://doi.org/10.1177/019262339902700115
doi: 10.1177/019262339902700115
pubmed: 10367678
U.S. department of health and human services (2017) Common terminology criteria for adverse events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . Accessed 15 January 2018
Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA 185:914–919. https://doi.org/10.1001/jama.1963.03060120024016
doi: 10.1001/jama.1963.03060120024016
pubmed: 14044222
Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186
doi: 10.1093/geront/9.3_Part_1.179
Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259. https://doi.org/10.1016/S0140-6736(00)02799-9
doi: 10.1016/S0140-6736(00)02799-9
pubmed: 11072960
Bannwarth B (2010) Critères d’imputabilité des effets indésirables des médicaments. Rev du Rhum 77:173–175. http://www.sciencedirect.com/science/article/pii/S187862271000041X . Accessed Apr 2010
Benedek TG (1988) Neoplastic associations of rheumatic diseases and rheumatic manifestations of cancer. Clin Geriatr Med 4:333–355
doi: 10.1016/S0749-0690(18)30752-3
Manzini CU, Colaci M, Ferri C, Manzini E (2018) Paraneoplastic rheumatic disorders: a narrative review. Reumatismo 70:199–211. https://doi.org/10.4081/reumatismo.2018.1069
doi: 10.4081/reumatismo.2018.1069
pubmed: 30570238
Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK et al (2018) Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Support Care Cancer 26:3073–3081. https://doi.org/10.1007/s00520-018-4161-x
doi: 10.1007/s00520-018-4161-x
pubmed: 29564623
Bondarenko IM, Bias P, Buchner A (2016) Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Support Care Cancer 24:267–273. https://doi.org/10.1007/s00520-015-2777-7
doi: 10.1007/s00520-015-2777-7
pubmed: 26024743
Watt FE (2018) Musculoskeletal pain and menopause. Post Reprod Health 24:34–43. https://doi.org/10.1177/2053369118757537
doi: 10.1177/2053369118757537
pubmed: 29412042
Touyz RM, Herrmann SMS, Herrmann J (2018) Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events. J Am Soc Hypertens 12:409–425. https://doi.org/10.1016/j.jash.2018.03.008
doi: 10.1016/j.jash.2018.03.008
pubmed: 29703600
pmcid: 6168784
Totzeck M, Mincu RI, Rassaf T (2017) Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc 6:e006278. https://doi.org/10.1161/JAHA.117.006278
doi: 10.1161/JAHA.117.006278
pubmed: 28862931
pmcid: 5586462
Lee S-P, Hsu H-C, Tai Y-J, Chen Y-L, Chiang Y-C, Chen C-A et al (2019) Bevacizumab dose affects the severity of adverse events in gynecologic malignancies. Front Pharmacol 10:426. https://doi.org/10.3389/fphar.2019.00426
doi: 10.3389/fphar.2019.00426
pubmed: 31105567
pmcid: 6498445
Ventriglia J, Paciolla I, Pisano C, Tambaro R, Cecere SC, Di Napoli M et al (2020) Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2020-001540
doi: 10.1136/ijgc-2020-001540
pubmed: 32796087
Giannakopoulos CK, Kyriakidou GK, Toufexi GE (2005) Palmar fasciitis and polyarthritis associated with secondary ovarian carcinoma. Case report Eur J Gynaecol Oncol 26:339–341
pubmed: 15991542
Martorell EA, Murray PM, Peterson JJ, Menke DM, Calamia KT (2004) Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am 29:654–660. https://doi.org/10.1016/j.jhsa.2004.04.012
doi: 10.1016/j.jhsa.2004.04.012
pubmed: 15249090